Literature DB >> 14757857

The allelic modulation of apolipoprotein E expression by oestrogen: potential relevance for Alzheimer's disease.

J-C Lambert1, N Coyle, C Lendon.   

Abstract

BACKGROUND: The epsilon4 allele of the apolipoprotein E (APOE) gene is a major genetic risk factor for Alzheimer's disease but appears to be associated with greater risk in women than in men. Some studies suggest that the level of APOE may of its own modulate the risk for Alzheimer's disease. Sex differences and an apparent benefit of oestrogen therapy suggest a role for oestrogen. APOE expression is influenced by oestrogen and oestrogen therapy may not benefit women bearing an APOE epsilon4 allele. These findings suggest an interaction between oestrogen and APOE in the Alzheimer's disease process. AIM: To explore the hypothesis that APOE expression is regulated by a genomic mechanism and is modified by the polymorphisms in APOE associated with risk for Alzheimer's disease.
METHODS: In vitro binding studies were undertaken between oestrogen receptors and fragments of the human APOE gene. APOE gene expression was studied to investigate a possible functional interaction.
RESULTS: APOE epsilon2/epsilon3/epsilon4 coding and -219 G/T promoter polymorphisms influenced binding to the oestrogen receptor and altered transcriptional activity in response to oestrogen.
CONCLUSIONS: An allele dependent modulation of oestrogen induced regulation of APOE might be involved in the increased risk for Alzheimer's disease in women bearing an epsilon4 allele.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14757857      PMCID: PMC1735679          DOI: 10.1136/jmg.2003.005033

Source DB:  PubMed          Journal:  J Med Genet        ISSN: 0022-2593            Impact factor:   6.318


  81 in total

Review 1.  Cellular and molecular basis of estrogen's neuroprotection. Potential relevance for Alzheimer's disease.

Authors:  N C Inestrosa; M P Marzolo; A B Bonnefont
Journal:  Mol Neurobiol       Date:  1998       Impact factor: 5.590

2.  Apolipoprotein E-epsilon4 genotype predicts a poor outcome in survivors of traumatic brain injury.

Authors:  G Friedman; P Froom; L Sazbon; I Grinblatt; M Shochina; J Tsenter; S Babaey; B Yehuda; Z Groswasser
Journal:  Neurology       Date:  1999-01-15       Impact factor: 9.910

3.  Postmenopausal estrogen replacement therapy and risk of AD: a population-based study.

Authors:  S C Waring; W A Rocca; R C Petersen; P C O'Brien; E G Tangalos; E Kokmen
Journal:  Neurology       Date:  1999-03-23       Impact factor: 9.910

4.  A cross-ethnic analysis of risk factors for AD in white Hispanics and white non-Hispanics.

Authors:  D G Harwood; W W Barker; D A Loewenstein; R L Ownby; P St George-Hyslop; M Mullan; R Duara
Journal:  Neurology       Date:  1999-02       Impact factor: 9.910

5.  Specific regional transcription of apolipoprotein E in human brain neurons.

Authors:  P T Xu; J R Gilbert; H L Qiu; J Ervin; T R Rothrock-Christian; C Hulette; D E Schmechel
Journal:  Am J Pathol       Date:  1999-02       Impact factor: 4.307

6.  Isoform-specific effects of human apolipoprotein E on brain function revealed in ApoE knockout mice: increased susceptibility of females.

Authors:  J Raber; D Wong; M Buttini; M Orth; S Bellosta; R E Pitas; R W Mahley; L Mucke
Journal:  Proc Natl Acad Sci U S A       Date:  1998-09-01       Impact factor: 11.205

7.  Sequence requirements for estrogen receptor binding to estrogen response elements.

Authors:  M D Driscoll; G Sathya; M Muyan; C M Klinge; R Hilf; R A Bambara
Journal:  J Biol Chem       Date:  1998-11-06       Impact factor: 5.157

8.  Pronounced impact of Th1/E47cs mutation compared with -491 AT mutation on neural APOE gene expression and risk of developing Alzheimer's disease.

Authors:  J C Lambert; C Berr; F Pasquier; A Delacourte; B Frigard; D Cottel; J Pérez-Tur; V Mouroux; M Mohr; D Cécyre; D Galasko; C Lendon; J Poirier; J Hardy; D Mann; P Amouyel; M C Chartier-Harlin
Journal:  Hum Mol Genet       Date:  1998-09       Impact factor: 6.150

9.  Risk for Alzheimer's disease correlates with transcriptional activity of the APOE gene.

Authors:  M J Artiga; M J Bullido; A Frank; I Sastre; M Recuero; M A García; C L Lendon; S W Han; J C Morris; J Vázquez; A Goate; F Valdivieso
Journal:  Hum Mol Genet       Date:  1998-11       Impact factor: 6.150

10.  The -491A/T apolipoprotein E promoter polymorphism association with Alzheimer's disease: independent risk and linkage disequilibrium with the known APOE polymorphism.

Authors:  T Town; D Paris; D Fallin; R Duara; W Barker; M Gold; F Crawford; M Mullan
Journal:  Neurosci Lett       Date:  1998-08-14       Impact factor: 3.046

View more
  15 in total

1.  Role of Apolipoprotein E, Cathepsin D, and Brain-Derived Neurotrophic Factor in Parkinson's Disease: A Study from Eastern India.

Authors:  Prosenjit Pal; Tamal Sadhukhan; Subhadip Chakraborty; Sriparna Sadhukhan; Arindam Biswas; Shyamal K Das; Kunal Ray; Jharna Ray
Journal:  Neuromolecular Med       Date:  2019-05-28       Impact factor: 3.843

2.  Is there a relation between APOE expression and brain amyloid load in Alzheimer's disease?

Authors:  J-C Lambert; D Mann; F Richard; J Tian; J Shi; U Thaker; S Merrot; J Harris; B Frigard; T Iwatsubo; C Lendon; P Amouyel
Journal:  J Neurol Neurosurg Psychiatry       Date:  2005-07       Impact factor: 10.154

3.  GAB2 gene does not modify the risk of Alzheimer's disease in Spanish APOE 4 carriers.

Authors:  R Ramirez-Lorca; M Boada; M E Saez; I Hernandez; A Mauleon; M Rosende-Roca; P Martinez-Lage; M Gutierrez; L M Real; J Lopez-Arrieta; J Gayan; C Antunez; A Gonzalez-Perez; L Tarraga; A Ruiz
Journal:  J Nutr Health Aging       Date:  2009-03       Impact factor: 4.075

4.  The effects of an APOE promoter polymorphism on human cortical morphology during nondemented aging.

Authors:  Yaojing Chen; Peng Li; Bin Gu; Zhen Liu; Xin Li; Alan C Evans; Gaolang Gong; Zhanjun Zhang
Journal:  J Neurosci       Date:  2015-01-28       Impact factor: 6.167

Review 5.  A Quarter Century of APOE and Alzheimer's Disease: Progress to Date and the Path Forward.

Authors:  Michaël E Belloy; Valerio Napolioni; Michael D Greicius
Journal:  Neuron       Date:  2019-03-06       Impact factor: 17.173

6.  APOE -491 T allele may reduce the risk of atherosclerotic lesions among middle-aged women.

Authors:  Virginia G Bañares; Ariel Bardach; Graciela Peterson; Marcelo J Tavella; Laura E Schreier
Journal:  Mol Cell Biochem       Date:  2011-11-22       Impact factor: 3.396

7.  The apolipoprotein E epsilon4 allele selectively increases the risk of frontotemporal lobar degeneration in males.

Authors:  R Srinivasan; Y Davidson; L Gibbons; A Payton; A M T Richardson; A Varma; C Julien; C Stopford; J Thompson; M A Horan; N Pendleton; S M Pickering-Brown; D Neary; J S Snowden; D M A Mann
Journal:  J Neurol Neurosurg Psychiatry       Date:  2006-02       Impact factor: 10.154

8.  Potential role of estrogen in the pathobiology and prevention of Alzheimer's disease.

Authors:  Whitney Wharton; Carey E Gleason; Katelin R Lorenze; Tamara S Markgraf; Michele L Ries; Cynthia M Carlsson; Sanjay Asthana
Journal:  Am J Transl Res       Date:  2009-01-20       Impact factor: 4.060

Review 9.  Estrogen receptor β in Alzheimer's disease: From mechanisms to therapeutics.

Authors:  Liqin Zhao; Sarah K Woody; Anindit Chhibber
Journal:  Ageing Res Rev       Date:  2015-08-22       Impact factor: 10.895

10.  Variation in 5' promoter region of the APOE gene contributes to predicting ischemic heart disease (IHD) in the population at large: the Copenhagen City Heart Study.

Authors:  J H Stengård; R Frikke-Schmidt; A Tybjaerg-Hansen; B G Nordestgaard; C F Sing
Journal:  Ann Hum Genet       Date:  2007-05-29       Impact factor: 1.670

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.